Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Recommendation of “Buy” from Analysts

Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) have been assigned an average rating of “Buy” from the seven analysts that are presently covering the firm, MarketBeat Ratings reports. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $11.00.

ACRS has been the topic of a number of research reports. Jefferies Financial Group raised shares of Aclaris Therapeutics from a “hold” rating to a “buy” rating and raised their target price for the company from $2.00 to $7.00 in a research report on Tuesday, November 19th. StockNews.com lowered shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 8th. Cantor Fitzgerald upgraded shares of Aclaris Therapeutics to a “strong-buy” rating in a research note on Thursday, January 30th. BTIG Research upgraded shares of Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $8.00 price objective for the company in a research note on Tuesday, November 19th. Finally, HC Wainwright upgraded shares of Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $20.00 price objective for the company in a research note on Monday, December 23rd.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ACRS. Adage Capital Partners GP L.L.C. acquired a new position in Aclaris Therapeutics during the 4th quarter valued at approximately $23,876,000. Vivo Capital LLC acquired a new position in Aclaris Therapeutics during the 4th quarter valued at approximately $22,044,000. RA Capital Management L.P. acquired a new position in Aclaris Therapeutics during the 4th quarter valued at approximately $11,573,000. Rock Springs Capital Management LP increased its stake in Aclaris Therapeutics by 125.3% during the 4th quarter. Rock Springs Capital Management LP now owns 6,204,309 shares of the biotechnology company’s stock valued at $15,387,000 after purchasing an additional 3,450,814 shares in the last quarter. Finally, Janus Henderson Group PLC acquired a new position in Aclaris Therapeutics during the 4th quarter valued at approximately $6,985,000. Institutional investors and hedge funds own 98.34% of the company’s stock.

Aclaris Therapeutics Stock Performance

NASDAQ ACRS opened at $1.96 on Tuesday. The company has a market capitalization of $140.00 million, a price-to-earnings ratio of -3.77 and a beta of 0.50. The company’s 50-day simple moving average is $2.42 and its two-hundred day simple moving average is $2.17. Aclaris Therapeutics has a one year low of $0.95 and a one year high of $5.17.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.